Skip to main content

Advertisement

Table 4 Results of ADA treatment for the prevention of postoperative recurrence

From: Clinical efficacy of adalimumab in Crohn’s disease: a real practice observational study in Japan

Basic characteristic Risk factor Clinical remission (last examination) Endoscopy (last examination)
Patient Gender Age (years) Disease duration (months) Disease location Previous IFX Time to ADA after resection (days) Smoking Penetrating disease Previous resection Disease duration (<10 years) Numbers of risk factors Time to last examination (months) Remission Time to Endoscopy(months) Rutgeerts score Mucosal healing
1 M 33 153 Ileocolonic 43 × × 2 48 20 i0
2 M 32 77 Ileocolonic 18 4 50 44 i4 ×
3 M 38 96 Ileocolonic × 23 × 3 49 47 i0
4 M 30 178 Ileo 57 × × 2 46 × 37 i3 ×
5 M 29 3 Ileocolonic × 40 × × 2 40 28 i2 ×
6 M 50 276 Ileo × 49 × × × 1 32 23 i0
7 M 19 8 Ileocolonic × 15 × × 2 38 22 i0
8 M 50 480 Ileocolonic 23 × × 2 38 38 i1
9 M 34 180 Ileo 60 × × 2 31 8 i0
10 M 33 120 Ileo × 240 × × 2 29 28 i2 ×
11 M 43 204 Ileocolonic × 73 × × 2 32 - - -
12 M 47 36 Ileocolonic × 53 × 3 24 - - -
13 M 23 18 Ileocolonic × 22 × × 2 15 8 i0
14 F 45 396 Ileocolonic × 82 × × 2 24 24 i3 ×
15 M 27 3 Ileocolonic × 10 × × × 1 16 15 i0
16 F 31 18 Ileocolonic × 38 × × 2 12 12 i0
Total M/F: 14/2 35.3 140.4 4/12 31.3 % (5/16) 52.9 31.3 % (5/16) 68.8 % (11/16) 56.3 % (9/16) 56.3 % (9/16) 2.1 32.3 93.8 % (15/16) 25.3 - 64.3 % (9/14)
  1. Parametric variables as total are shown as mean or rates
  2. ADA adalimumab, IFX infliximab